Following Fresenius
German healthcare group Fresenius showed its might last week when it amended a $1.2bn syndicated loan, as a result cutting its interest payments substantially. It’s not just good news for the company: if history is a guide, then where Fresenius goes, others soon follow.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
